





Item 7.01 Regulation FD Disclosure.

On January 9, 2017, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing the commencement of patient enrollment in China for its CALL-1 (“CAR-T against Acute Lymphoblastic Leukemia”) Phase I clinical trial utilizing its optimized proprietary C-CAR011 construct of CD19 chimeric antigen receptor T-cell (“CAR-T”) therapy for the treatment of patients with relapsed or refractory (r/r) CD19+ B-cell Acute Lymphoblastic Leukemia. A copy of the press release is attached hereto as Exhibit 99.1.

Attached as Exhibit 99.2 to this Current Report is the form of presentation that the Company will be using in connection with its presentation to certain potential investors at the 9th Annual Biotech Showcase conference on January 10, 2017 in San Francisco, California.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release, dated January 9, 2017

99.2 Presentation



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group,  
Inc.

Date: January 9, 2017 By: /s/ Bizuo (Tony) Liu  
Bizuo (Tony) Liu  
Chief Executive Officer